Three abstracts that evaluate the efficacy and safety of cantharidin (VP-102) were presented by Verrica Pharmaceuticals at the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Cantharidin is intended to provide beneficial treatments for people living with skin diseases, such as molluscum contagiosum and common warts.

The positive results come from a pooled analysis of the phase 3 CAMP-1 and CAMP-2 clinical studies, which showed treatment with cantharidin brought about a significantly higher rate of complete lesion clearance by Day 84. In addition, the mean lesion count decreased by 76% for subjects in the cantharidin group.

The second pooled analysis of the CAMP studies demonstrated that as early as Day 21, 90% of lesions were reduced, and lesion clearance in patients using cantharidin were between 75-90% compared to the vehicle.

The adverse events reported from the studies included application site vesicles, pruritis, pain, erythema, and scab.


Verrica Pharmaceuticals announces presentation of positive data from clinical trials of VP-102 at the 2019 annual fall clinical dermatology conference [news release]. West Chester, PA; Verrica Pharmaceuticals News Releases: October 18, 2019. Accessed October 18, 2019.